These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31142500)

  • 21. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
    Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
    J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.
    Park G; Park JK; Son DS; Shin SH; Kim YJ; Jeon HJ; Lee J; Park WY; Lee KH; Park D
    Sci Rep; 2018 Aug; 8(1):11631. PubMed ID: 30072705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
    Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
    Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
    J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.
    Till JE; McDaniel L; Chang C; Long Q; Pfeiffer SM; Lyman JP; Padrón LJ; Maurer DM; Yu JX; Spencer CN; Gherardini PF; Da Silva DM; LaVallee TM; Abbott C; Chen RO; Boyle SM; Bhagwat N; Cannas S; Sagreiya H; Li W; Yee SS; Abdalla A; Wang Z; Yin M; Ballinger D; Wissel P; Eads J; Karasic T; Schneider C; O'Dwyer P; Teitelbaum U; Reiss KA; Rahma OE; Fisher GA; Ko AH; Wainberg ZA; Wolff RA; O'Reilly EM; O'Hara MH; Cabanski CR; Vonderheide RH; Carpenter EL
    Nat Commun; 2024 Jul; 15(1):5763. PubMed ID: 38982051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
    Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
    Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
    Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
    Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.
    Watanabe K; Nakamura T; Kimura Y; Motoya M; Kojima S; Kuraya T; Murakami T; Kaneko T; Shinohara Y; Kitayama Y; Fukuda K; Hatanaka KC; Mitsuhashi T; Pittella-Silva F; Yamaguchi T; Hirano S; Nakamura Y; Low SK
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
    Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
    Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
    [No Abstract]   [Full Text] [Related]  

  • 37. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.
    Yang Z; LaRiviere MJ; Ko J; Till JE; Christensen T; Yee SS; Black TA; Tien K; Lin A; Shen H; Bhagwat N; Herman D; Adallah A; O'Hara MH; Vollmer CM; Katona BW; Stanger BZ; Issadore D; Carpenter EL
    Clin Cancer Res; 2020 Jul; 26(13):3248-3258. PubMed ID: 32299821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.
    Slater S; Bryant A; Aresu M; Begum R; Chen HC; Peckitt C; Lazaro-Alcausi R; Carter P; Anandappa G; Khakoo S; Melcher L; Potter V; Marti FM; Huang J; Branagan G; George N; Abulafi M; Duff S; Raja A; Gupta A; West N; Bucheit L; Rich T; Chau I; Cunningham D; Starling N;
    Clin Cancer Res; 2024 Aug; 30(16):3459-3469. PubMed ID: 38864835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
    Botta GP; Abdelrahim M; Drengler RL; Aushev VN; Esmail A; Laliotis G; Brewer CM; George GV; Abbate SM; Chandana SR; Tejani MA; Malla M; Bansal D; Rivero-Hinojosa S; Spickard E; McCormick N; Cecchini M; Lacy J; Fei N; Kasi PM; Kasi A; Dayyani F; Hanna DL; Sharma S; Malhotra M; Aleshin A; Liu MC; Jurdi A
    Oncologist; 2024 Oct; 29(10):859-869. PubMed ID: 39022993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.